PF-6883541

N/A

Report date: 2024/01/19 15:03:55

Base Information

Drug NamePF-6883541

Drug Alias NamePF-6883541PF-06883541

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy

Mechanisms of ActionT lymphocyte replacementsB-lymphocyte antigen CD19 inhibitors

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesPfizer Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesPfizer Inc Allogene Therapeutics Inc

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A